AMENDMENT NO. 1 TO STOCKHOLDERS AGREEMENT
Exhibit 4.8
AMENDMENT NO. 1 TO STOCKHOLDERS AGREEMENT
THIS AMENDMENT NO. 1 TO STOCKHOLDERS AGREEMENT is entered into effective this 3rd day of
October, 2006 (this “Amendment No. 1”), by and among Cardiovascular Systems, Inc., a Minnesota
Corporation (the “Company”) , ITX International Equity Corp., a Delaware corporation (“ITX”), and
the Holders and Investors signatory hereto.
RECITALS
WHEREAS, this Amendment No. 1 amends a Stockholders Agreement, dated July 19, 2006 (the
“Stockholders Agreement”) by and between the Company and the “Holders”, “Investors”, and “Section 5
Holders” set forth on Schedule I thereto;
WHEREAS, the Company has agreed to sell 350,263 shares of Series A Convertible Preferred Stock
and a warrant to purchase up to 49,737 shares of Series A Convertible Preferred Stock to ITX in
accordance with the terms of that certain Stock Purchase Agreement by and between the Company and
ITX of even date herewith (the “Stock Purchase Agreement”);
WHEREAS, Holders executing this Amendment No. 1 hold a majority of the Shares subject to the
Stockholders Agreement; and
WHEREAS, Investors executing this Amendment No. 1 hold a majority in interest of the shares
of Common Stock issued or issuable to the Investors.
NOW THEREFORE, in consideration of the mutual covenants and agreements contained in this
Amendment No. 1, the sufficiency of which is hereby acknowledged, the parties hereto agree as set
forth below:
1. | Defined Terms. Capitalized terms not defined herein shall have the meanings ascribed to them in the Stockholders Agreement. | ||
2. | Schedule I is hereby amended to include ITX as an Investor as set forth below and ITX shall be deemed an Investor as that term is used in the Stockholders Agreement. |
No. of Shares | ||||||||||||||||
No. of | of Series A | No. of Series | ||||||||||||||
No. of Shares of | Option/Warrant | Preferred | A Warrant | |||||||||||||
Investor | Common Stock | Common Shares | Stock | Shares | ||||||||||||
ITX International Equity Corp. |
0 | 0 | 350,263 | 49,737 | ||||||||||||
000 X. Xx Xxxxxx Xxxx |
||||||||||||||||
Xxxxx 000 |
||||||||||||||||
Xxxxxxxx Xxxx, XX 00000 |
3. | This Amendment No. 1 may be executed in any number of original or facsimile counterparts, and each such counterpart hereof shall be deemed to be an original |
1
instrument, but all such counterparts together shall constitute but one agreement. Any counterpart or other signature to this Amendment No. 1 that is delivered by facsimile shall be deemed for all purposes as constituting good and valid execution and delivery by such party of this Amendment No. 1. | |||
4. | Except as set forth herein, all other terms and conditions of the Stockholders Agreement remain the same. |
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
2
IN WITNESS WHEREOF, the parties hereto have executed this Amendment No. 1 to Stockholders
Agreement effective the date first written above.
COMPANY CARDIOVASCULAR SYSTEMS, INC. |
||||
By: | /s/ Xxxxxxx X. Xxxxxx | |||
Name: | Xxxxxxx X. Xxxxxx | |||
Title: | Chief Executive Officer and President |
3
IN WITNESS WHEREOF, the parties hereto have executed this Amendment No. 1 to Stockholders
Agreement effective the date first written above.
HOLDERS
APPLECREST PARTNERS LTD PARTNERSHIP | ||
By:
|
/s/ Xxxx X. Xxxxxxxx | |
Name: Xxxx X. Xxxxxxxx | ||
Title: General Partner | ||
/s/ Xxxx X. Xxxxxxxx | ||
Xxxx X. Xxxxxxxx | ||
/s/ Xxxxx X. Xxxxxxxx | ||
Xxxxx X. Xxxxxxxx | ||
GDN HOLDINGS, LLC | ||
By:
|
/s/ Xxxx X. Xxxxxx | |
Name: Xxxx X. Xxxxxx | ||
Title: Member | ||
/s/ Xxxxxxxx X. Xxxxxxxx | ||
Xxxxxxxx X. Xxxxxxxx, individually and as Trustee, Xxxxxxxx X. Xxxxxxxx Rev. Trust dtd 1/8/97, as amended | ||
/s/ Xxxxxxx X. Xxxxxx | ||
Xxxxxxx X. Xxxxxx |
XXXXXXXX FAMILY LIMITED PARTNERSHIP | ||
By:
|
/s/ Xxxxx X. Xxxxxxxx | |
Name: Xxxxx X. Xxxxxxxx | ||
Title: | ||
/s/ Xxxxx X. Xxxxxxxx | ||
Xxxxx X. Xxxxxxxx | ||
/s/ Xxxxxx X. Xxxxxxxx | ||
Xxxxxx X. Xxxxxxxx | ||
SONORA WEB LIMITED LIABILITY PARTNERSHIP | ||
By:
|
/s/ Xxxxx X. Xxxx | |
Name: Xxxxx X. Xxxx | ||
Title: | ||
/s/ Xxxxx X. Xxxx | ||
Xxxxx X. Xxxx, Ph. D. | ||
/s/ Xxxxxx X. Xxxxxxxx | ||
Xxxxxx X. Xxxxxxxx | ||
/s/ Xxxxx X. Xxxxx | ||
Xxxxx X. Xxxxx, Ph.D. |
4
IN WITNESS WHEREOF, the parties hereto have executed this Amendment No. 1 to Stockholders
Agreement effective the date first written above.
INVESTORS | ||||
EASTON XXXX CAPITAL PARTNERS, L.P. | ||||
By: EHC GP, L.P. its General Partner | ||||
By: EHC GP, Inc., its General Partner | ||||
By: | /s/ Xxxx X. Xxxxxxxx | |||
Name: Xxxx X. Xxxxxxxx | ||||
Title: President | ||||
EASTON CAPITAL PARTNERS, LP | ||||
By: ECP GP, LLC | ||||
By: ECP GP, Inc., its Manager | ||||
By: | /s/ Xxxx X. Xxxxxxxx | |||
Name: Xxxx X. Xxxxxxxx | ||||
Title: President |
5
IN WITNESS WHEREOF, the parties hereto have executed this Amendment No. 1 to Stockholders
Agreement effective the date first written above.
INVESTORS | ||||
MAVERICK FUND, L.D.C. | ||||
By: | Maverick Capital, Ltd. | |||
Its Investment Advisor | ||||
By: | /s/ Xxxxxxx Xxxxxxx | |||
Name: Xxxxxxx Xxxxxxx | ||||
Title: Managing Director | ||||
MAVERICK FUND USA, LTD. | ||||
By: | Maverick Capital, Ltd. | |||
Its Investment Advisor | ||||
By: | /s/ Xxxxxxx Xxxxxxx | |||
Name: Xxxxxxx Xxxxxxx | ||||
Title: Managing Director | ||||
MAVERICK FUND II, LTD. | ||||
By: | Maverick Capital, Ltd. | |||
Its Investment Advisor | ||||
By: | /s/ Xxxxxxx Xxxxxxx | |||
Name: Xxxxxxx Xxxxxxx | ||||
Title: Managing Director |
6
IN WITNESS WHEREOF, the parties hereto have executed this Amendment No. 1 to Stockholders
Agreement effective the date first written above.
INVESTORS MITSUI & CO. VENTURE PARTNERS II, L.P. |
||||
By: | Mitsui & Co. Venture Partners, Inc. | |||
Its General Partner | ||||
By: | /s/ Xxxxxx Xxxx | |||
Name: | Xxxxxx Xxxx | |||
Title: | President & CEO |
7
IN WITNESS WHEREOF, the parties hereto have executed this Amendment No. 1 to Stockholders
Agreement effective the date first written above.
INVESTORS ITX INTERNATIONAL EQUITY CORP. |
||||
By: | /s/ Takehito Jimbo | |||
Name: | Takehito Jimbo | |||
Title: | President and Chief Executive Officer | |||
8